Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Christoph Domenig is active.

Publication


Featured researches published by Christoph Domenig.


Nature Immunology | 2003

Tim-3 inhibits T helper type 1-mediated auto- and alloimmune responses and promotes immunological tolerance.

Alberto Sanchez-Fueyo; Jane Tian; Dominic Picarella; Christoph Domenig; Xin Xiao Zheng; Catherine A. Sabatos; Natasha Manlongat; Orissa Bender; Thomas Kamradt; Vijay K. Kuchroo; Jose-Carlos Gutierrez-Ramos; Anthony J. Coyle; Terry B. Strom

Although T helper (TH) cell–mediated immunity is required to effectively eliminate pathogens, unrestrained TH activity also contributes to tissue injury in many inflammatory and autoimmune diseases. We report here that the TH type 1 (TH1)-specific Tim-3 (T cell immunoglobulin domain, mucin domain) protein functions to inhibit aggressive TH1-mediated auto- and alloimmune responses. Tim-3 pathway blockade accelerated diabetes in nonobese diabetic mice and prevented acquisition of transplantation tolerance induced by costimulation blockade. These effects were mediated, at least in part, by dampening of the antigen-specific immunosuppressive function of CD4+CD25+ regulatory T cell populations. Our data indicate that the Tim-3 pathway provides an important mechanism to down-regulate TH1-dependent immune responses and to facilitate the development of immunological tolerance.


Immunity | 2003

Favorably tipping the balance between cytopathic and regulatory T cells to create transplantation tolerance

Xin Xiao Zheng; Alberto Sanchez-Fueyo; Masayuki Sho; Christoph Domenig; Mohamed H. Sayegh; Terry B. Strom

Therapeutic application of broadly reactive anti-T cell antibodies can lead not only to potent immunosuppression but also to profound and long-lived T cell depletion. We reasoned that a strategy that almost exclusively targets activated cytopathic donor reactive T cells and spares immunoregulatory networks might prove to be an exceptionally potent and highly selective means of producing long-term engraftment and tolerance. Herein we show that the combined administration of rapamycin and agonist IL-2- and antagonist IL-15-related cytolytic fusion proteins provides for long-term engraftment/tolerance in exceptionally stringent allotransplant models by (1) limiting the early expansion of activated T cells, (2) preserving and even exaggerating their subsequent apoptotic clearance, and (3) further amplifying the depletion of these activated T cells by antibody-dependent mechanisms, while (4) preserving CD4+CD25+ T cell-dependent immunoregulatory networks.


Journal of Immunology | 2002

Tracking the Immunoregulatory Mechanisms Active During Allograft Tolerance

Alberto Sanchez-Fueyo; Martina Weber; Christoph Domenig; Terry B. Strom; Xin Xiao Zheng

Immunoregulatory mechanisms dependent on regulatory CD4+ T cells are believed to be critical in the maintenance of peripheral tolerance to allografts. However, a detailed characterization of the effects of these regulatory T cells has been hampered by the absence of a simple means to track and study them. In this work we provide evidence that in a murine model of islet transplantation the interactions between alloaggressive and regulatory T cells can be studied in vitro and in vivo at the single-cell level. The observations made in both an in vitro coculture system and an in vivo CFSE-based adoptive transfer model indicate that lymphocytes from tolerant allograft recipients 1) proliferate weakly to donor strain allogeneic cells but vigorously to third-party strain cells; and 2) suppress the proliferation of naive syngeneic CD4+ and CD8+ T cells to donor tissue in a cell dose- and Ag-specific manner. These effects depend on the presence of CD4+CD25+ T cells and are neutralized by anti-CTLA4 mAb or rIL-2. The principal effect of anti-CTLA4 is directed against the naive, not regulatory, T cell population. These results can be replicated in vivo by transferring lymphocyte populations into transplant recipients, proving that the graft-protecting actions of regulatory T cells are blunted by a rise in the number of allodestructive T cells (pool size model) and depend on the presence of CD4+CD25+ T cells and the integrity of the CTLA4/B7 pathway.


Journal of Immunology | 2005

Role of the Programmed Death-1 Pathway in Regulation of Alloimmune Responses In Vivo

Michael R. Clarkson; Alan D. Salama; Alberto Sanchez-Fueyo; Christoph Domenig; Antje Habicht; Nader Najafian; Hideo Yagita; Miyuki Azuma; Laurence A. Turka; Mohamed H. Sayegh

Programmed death-1 (PD-1), an inhibitory receptor up-regulated on activated T cells, has been shown to play a critical immunoregulatory role in peripheral tolerance, but its role in alloimmune responses is poorly understood. Using a novel alloreactive TCR-transgenic model system, we examined the functions of this pathway in the regulation of alloreactive CD4+ T cell responses in vivo. PD-L1, but not PD-1 or PD-L2, blockade accelerated MHC class II-mismatched skin graft (bm12 (I-Abm12) into B6 (I-Ab)) rejection in a similar manner to CTLA-4 blockade. In an adoptive transfer model system using the recently described anti-bm12 (ABM) TCR-transgenic mice directly reactive to I-Abm12, PD-1 and PD-L1 blockade enhanced T cell proliferation early in the immune response. In contrast, at a later time point preceding accelerated allograft rejection, only PD-L1 blockade enhanced T cell proliferation. In addition, PD-L1 blockade enhanced alloreactive Th1 cell differentiation. Apoptosis of alloantigen-specific T cells was inhibited significantly by PD-L1 but not PD-1 blockade, indicating that PD-1 may not be the receptor for the apoptotic effect of the PD-L1-signaling pathway. Interestingly, the effect of PD-L1 blockade was dependent on the presence of CD4+CD25+ regulatory T cells in vivo. These data demonstrate a critical role for the PD-1 pathway, particularly PD-1/PD-L1 interactions, in the regulation of alloimmune responses in vivo.


Immunological Reviews | 2003

The balance of deletion and regulation in allograft tolerance

Xin Xiao Zheng; Alberto Sanchez-Fueyo; Christoph Domenig; Terry B. Strom

Summary:  Although the precise mechanisms involved in the establishment and maintenance of peripheral allograft tolerance are still not fully understood, it is now clear that acquisition of transplantation tolerance is an active, highly regulated, multistep process. According to the pool size model of allograft tolerance, the allograft outcome, rejection, or tolerance, often depends on the balance between cytopathic and regulatory T cells (Tregs). Although both deletion and regulation play important roles in allograft tolerance, our recent studies showed that the quantitative details for each mechanism differ from model to model. Therefore, we hypothesize that there is a delicate balance between deletion and regulation in allograft tolerance. In a model of allograft tolerance in which the deletional mechanism plays a dominant role, e.g. tolerance produced via creation of mixed chimeras, the regulatory mechanism, albeit sometimes present, is far less important. Whilst in a model in which the regulation mechanism plays a critical role, e.g. donor‐specific transfusion plus MR1‐induced allograft tolerance, a deletional mechanism lowers the threshold for effective Treg action.


Journal of Immunology | 2005

Roles of Deletion and Regulation in Creating Mixed Chimerism and Allograft Tolerance Using a Nonlymphoablative Irradiation-Free Protocol

Christoph Domenig; Alberto Sanchez-Fueyo; John M. Kurtz; Sophoclis Alexopoulos; Christophe Mariat; Megan Sykes; Terry B. Strom; Xin Xiao Zheng

The induction of mixed chimerism (MC) is a powerful and effective means to achieve transplantation tolerance in rodent models. Host conditioning with irradiation or cytotoxic drugs has been used in many protocols for chimeric induction across allogeneic barriers. The deletion of alloreactive T cell clones has been described as the main mechanism responsible for the induction of a stable MC. In this study, we demonstrate that a stable MC and skin allograft tolerance can be established across MHC barriers by a noncytotoxic, irradiation-free approach using costimulation blockade plus rapamycin treatment. By using an adoptive transfer model of skin allograft and using specific Vβ TCR probes, we demonstrated that deletion of donor-reactive cytopathic T cell clones is indeed profound in tolerant hosts. Nonetheless, the challenge of tolerant mixed chimeras with 5 million mononuclear leukocytes (MNL) from naive syngeneic mice was neither able to abolish the stable MC nor to trigger skin allograft rejection, a hallmark of peripheral, not central tolerance. Furthermore, in an adoptive transfer model, MNLs harvested from tolerant hosts significantly inhibited the capacity of naive MNLs to reject same donor, but not third-party, skin allografts. Moreover, when we transplanted skin allografts from stable tolerant chimeras onto syngeneic immune-incompetent mice, graft-infiltrating T cells migrated from the graft site, expanded in the new host, and protected allografts from acute rejection by naive syngeneic MNLs. In this model, both deletional and immunoregulatory mechanisms are active during the induction and/or maintenance of allograft tolerance through creation of MC using a potentially clinically applicable regimen.


Transplant International | 2007

Influence of direct and indirect allorecognition pathways on CD4+CD25+ regulatory T-cell function in transplantation.

Alberto Sanchez-Fueyo; Christoph Domenig; Christophe Mariat; Sophoclis Alexopoulos; Xin X. Zheng; Terry B. Strom

While both direct and indirect allorecognition are involved in allograft rejection, evidence to date suggests that tolerance is primarily dependent on indirect pathway‐triggered CD4+CD25+ T cell‐mediated immunoregulation. However, the precise influence of these two pathways on CD4+CD25+ T‐cell function has not been addressed. In the current study, we have utilized an adoptive transfer model to assess selectively how the absence of either direct or indirect allorecognition affects CD4+CD25+ T‐cell function. The effects of the loss of the direct pathway were assessed by transplanting skin grafts from minor histocompatibility mismatched B10.D2 (H‐2d) donors onto Balb/c (H‐2d) recipients, or by placing bone marrow chimeric DBA/2 (H‐2d/H‐2b) allografts onto C57BL/6 (H‐2b) hosts. The requirement for indirect allorecognition was tested by grafting DBA/2 skin allografts onto either C57BL/6‐ or MHC‐II‐deficient C57BL/6 recipients. We report here that although CD4+CD25+ regulatory T cells can suppress both directly and indirectly generated alloresponses, immunoregulation is favored when indirect presentation is the sole mechanism of allorecognition. Hence, in the absence of indirect presentation, net CD4+CD25+ T cell‐dependent immunoregulation is weak, and high ratios of CD4+CD25+ to CD4+CD25− T cells are required to ensure graft survival.


Journal of Vascular Surgery | 2004

Bypass to plantar and tarsal arteries: an acceptable approach to limb salvage.

Kakra Hughes; Christoph Domenig; Allen D. Hamdan; Marc L. Schermerhorn; Bernadette Aulivola; Seth B. Blattman; David R. Campbell; Sherry D. Scovell; Frank W. LoGerfo; Frank B. Pomposelli


Urology | 2004

Anatomic basis of right renal vein extension for cadaveric kidney transplantation

Elisabeth Janschek; Alexander U Rothe; Thomas Hölzenbein; Felix B. Langer; Peter Christian Brugger; Herwig Pokorny; Christoph Domenig; Susanne Rasoul-Rockenschaub; Ferdinand Mühlbacher


Transplantation | 2002

The complement dependent cytotoxicity (CDC) immune effector mechanism contributes to anti-CD154 induced immunosuppression.

Alberto Sanchez-Fueyo; Christoph Domenig; Terry B. Strom; Xin Xiao Zheng

Collaboration


Dive into the Christoph Domenig's collaboration.

Top Co-Authors

Avatar

Terry B. Strom

Beth Israel Deaconess Medical Center

View shared research outputs
Top Co-Authors

Avatar

Xin Xiao Zheng

Beth Israel Deaconess Medical Center

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Allen D. Hamdan

Beth Israel Deaconess Medical Center

View shared research outputs
Top Co-Authors

Avatar

David R. Campbell

Beth Israel Deaconess Medical Center

View shared research outputs
Top Co-Authors

Avatar

Frank B. Pomposelli

Beth Israel Deaconess Medical Center

View shared research outputs
Top Co-Authors

Avatar

Frank W. LoGerfo

Beth Israel Deaconess Medical Center

View shared research outputs
Top Co-Authors

Avatar

Mohamed H. Sayegh

Brigham and Women's Hospital

View shared research outputs
Researchain Logo
Decentralizing Knowledge